WHAT IS CLAIMED IS:

1. A pharmaceutical composition multi-unit dosage form comprising at least three discrete unit dosage forms bound to one another by a coating and/or matrix, each of said unit dosage forms comprising a therapeutically active agent and an absorption enhancer, said unit dosage forms together comprising a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said coating and/or matrix ~~is~~ dissolves in gastric fluid within no more than 5 minutes ~~formulated for immediate~~ to thereby release ~~of~~ said unit dosage forms upon oral administration, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4- chlorobenzoyl)aminobutanoic acid) and salts thereof, ~~and~~ wherein at least 50 weight percent of the unit dosage forms consists of said absorption enhancer, and wherein said therapeutically active agent is a polypeptide having a molecular weight in a range of 0.5 kDa to 100 kDa.

~~2. The multi-unit dosage form according to claim 1, being capable of disintegrating in gastric fluid and/or in saliva to thereby release said unit dosage forms.~~

~~3. The multi-unit dosage form according to claim 1 or 2, wherein an area under curve (AUC) of plasma concentration of said therapeutically active agent upon oral administration of the multi-unit dosage form is characterized by an inter-subject coefficient of variation of less than 100 %.~~

42. The multi-unit dosage form according to ~~any one of claims 1 to 3~~claim 1, comprising from 3 to 10 of said discrete unit dosage forms.

~~5. The multi-unit dosage form according to any one of claims 1 to 4, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.~~

Formatted: Don't suppress line numbers

~~6. The multi-unit dosage form according to any one of claims 1 to 4, wherein said therapeutically active agent is a BCS Class III agent.~~

~~7. The multi-unit dosage form according to any one of claims 1 to 4, wherein said therapeutically active agent is a polypeptide.~~

~~8~~3. The multi-unit dosage form according to claim ~~7~~1 or 2, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof which exhibits a biological activity of parathyroid hormone.

~~9~~4. Use of the multi-unit dosage form of any one of claims 1 to ~~8~~ 3 in the manufacture of medicament for the treatment of a condition treatable by oral administration of said therapeutically active agent in a subject in need thereof.

~~10~~5. A use of a pharmaceutical composition unit dosage form comprising a therapeutically active agent and an absorption enhancer, in the manufacture of a medicament for the treatment of a condition treatable by said therapeutically active agent, said medicament being for concomitant oral administration of at least three of the unit dosage form within a span of no more than 60 minutes, wherein said at least three of said unit dosage form together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, ~~and~~ wherein at least 50 weight percent of the unit dosage form consists of said absorption enhancer, and wherein said therapeutically active agent is a polypeptide having a molecular weight in a range of 0.5 kDa to 100 kDa.

~~11~~6. The use according to claim ~~10~~5, wherein said medicament is for concomitant oral administration of from 3 to 10 of the unit dosage form.

~~12. The use according to claim 10 or 11, wherein said treatment comprises reducing a variability of Cmax and/or AUC of plasma concentrations of said therapeutically active agent.~~

~~13. The use according to any one of claims 10 to 12, wherein said medicament is for increasing a Cmax and/or a bioavailability of said therapeutically active agent.~~

~~14. The use according to any one of claims 10 to 13, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.~~

~~15. The use according to any one of claims 10 to 13, wherein said therapeutically active agent is a BCS Class III agent.~~

~~16. The unit dosage form for use according to any one of claims 10 to 13, wherein said therapeutically active agent is a polypeptide.~~

~~17~~7. The unit dosage form for use according to claim 5 or ~~16~~6, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof which exhibits a biological activity of parathyroid hormone.

~~18. A pharmaceutical composition unit dosage form comprising less than 200 µg of parathyroid hormone or a fragment thereof, and an absorption enhancer selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof.~~

~~19~~8. Use of ~~the~~ a pharmaceutical composition unit dosage form comprising less than 200 µg of parathyroid hormone or a fragment thereof which exhibits a biological activity of parathyroid hormone, and an absorption enhancer selected from the group

consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4- chlorobenzoyl)aminobutanoic acid) and salts thereof~~according to claim 18~~, in the manufacture of a medicament for the treatment of a condition treatable by said parathyroid hormone or a fragment thereof, said medicament being for concomitant oral administration of at least ~~two~~ three of said unit dosage form within a span of no more than 60 minutes, wherein said at least ~~two~~ three of said unit dosage form together comprise a therapeutically effective amount of said parathyroid hormone or ~~a~~ said fragment thereof and an effective amount of said absorption enhancer.

~~20~~9. The use according to claim ~~17 or 19~~8, wherein said condition treatable by said parathyroid hormone or a fragment thereof is selected from the group consisting of hypoparathyroidism, osteoporosis, and a medical condition associated with a bone fracture and/or bone defect.